

Supplementary Information

Investigation of Heart Lipids Changes in Acute β -AR activation Induced Sudden Cardiac Death by Time- of-Flight Secondary Ion Mass Spectrometry

Jia-Qian Lou^{1†}, Yue Cao^{1†}, You-Jia Yu¹, Li Hu¹, Zheng-Sheng Mao¹, Ping Huang², Xin Hua^{3*},
Feng Chen^{1,4*}

1. Department of Forensic Medicine, Nanjing Medical University, Nanjing, Jiangsu, 211166, PR China.
2. Shanghai Key Laboratory of Forensic Medicine, Shanghai Forensic Service Platform, Academy of Forensic Science, Shanghai, 200063, China.
3. Department of Chemistry, East China University of Science and Technology, 130 Meilong Road, Shanghai, 200237, China.
4. Key Laboratory of Targeted Intervention of Cardiovascular Disease, Collaborative Innovation Center for Cardiovascular Disease Translational Medicine, Nanjing Medical University, Nanjing, Jiangsu, 211166, PR China

14th August 2020

Note added after first publication: This Supplementary Information file replaces that originally published on 25th June in which there were errors in Table S1.

[†]These authors contribute equally.

*Corresponding Author:

Phone: +(86) 25 86869342; Fax: +(86) 25 86862896

Email:

fchen@njmu.edu.cn (F.C.)

xinhua@ecust.edu.cn (X.H.)

TABLE OF CONTENTS

Fig.S1

Supplementary ToF-SIMS spectra of myocardium in NC and SCD mice in positive ion mode.

Fig.S2

Micrographs of heart from human case.

Table.S1

Lipid positive and negative ion species assigned by ToF-SIMS analysis.

Table.S2

Comparison of lipids in positive mode between human and mice samples.




Fig.S1 Supplementary positive ToF-SIMS spectra of myocardium in NC (A) and SCD (B) mice.




Fig.S2 Micrographs of heart from human case indicated myocardial degeneration.

Table.S1 Lipid positive and negative ion species assigned by ToF-SIMS analysis.

Experimental Value(m/z)	Theoretical Value (m/z)	Tentative identification	Ions	Formula
184.08	184.1 ¹	PC fragment		C ₅ H ₁₅ NPO ₄ ⁺
206.08	206.1 ²	PC fragment		C ₅ H ₁₄ NPO ₄ Na ⁺
224.11	224.1 ²	PC fragment		C ₈ H ₁₉ NPO ₄ ⁺
246.07	246.1 ²	PC fragment		C ₈ H ₁₈ NPO ₄ Na ⁺
264.25	264.32 ³⁻⁵	SG fragment		C ₁₈ H ₃₂ O ⁺
302.80	302.76 ⁶	SA	[M + H] ⁺	C ₁₈ H ₃₉ NO ₂ ⁺
309.20	309.34 ⁷	MAG 16:2	[M - OH] ⁺	C ₁₉ H ₃₃ O ₃ ⁺
311.27	311.26 ⁷	MAG 16:1	[M - OH] ⁺	C ₁₉ H ₃₅ O ₃ ⁺
313.27	313.27 ⁷	MAG 16:0	[M - OH] ⁺	C ₁₉ H ₃₇ O ₃ ⁺
339.27	339.29 ⁷	MAG 18:1	[M - OH] ⁺	C ₂₁ H ₃₉ O ₃ ⁺
341.30	341.31 ⁷	MAG 18:0	[M - OH] ⁺	C ₂₁ H ₄₁ O ₃ ⁺
369.31	369.35 ⁷	Cholesterol	[M - OH] ⁺	C ₂₇ H ₄₅ ⁺
385.31	385.35 ⁷	Cholesterol	[M - H] ⁺	C ₂₇ H ₄₅ O ⁺
430.37	430.38 ⁷	Vitamin E	M ⁺	C ₂₉ H ₅₀ O ₂ ⁺
478.31	478.33 ⁸	LysoPC 16:0	[M - OH] ⁺	C ₂₄ H ₄₈ NPO ₆ ⁺
492.33	492.33 ⁸	LysoPC 16:2	[M + H] ⁺	C ₂₄ H ₄₆ NPO ₇ ⁺
494.29	494.33 ⁸	LysoPC 16:1	[M + H] ⁺	C ₂₄ H ₄₈ NPO ₇ ⁺
496.29	496.34 ⁸	LysoPC 16:0	[M + H] ⁺	C ₂₄ H ₅₀ NPO ₇ ⁺
519.33	519.44 ⁷	DAG 30:2	[M - OH] ⁺	C ₃₃ H ₅₉ O ₄ ⁺
521.31	521.46 ⁷	DAG 30:1	[M - OH] ⁺	C ₃₃ H ₆₁ O ₄ ⁺
523.34	523.47 ⁷	DAG 30:0	[M - OH] ⁺	C ₃₃ H ₆₃ O ₄ ⁺
547.47	547.47 ⁷	DAG 32:2	[M - OH] ⁺	C ₃₅ H ₆₃ O ₄ ⁺
549.41	549.49 ⁷	DAG 32:1	[M - OH] ⁺	C ₃₅ H ₆₅ O ₄ ⁺
551.49	551.50 ⁷	DAG 32:0	[M - OH] ⁺	C ₃₅ H ₆₇ O ₄ ⁺
573.36	573.49 ⁷	DAG 34:2	[M - OH] ⁺	C ₃₇ H ₆₅ O ₄ ⁺
575.37	575.5 ⁷	DAG 34:1	[M - OH] ⁺	C ₃₇ H ₆₇ O ₄ ⁺
577.38	577.52 ⁷	DAG 34:0	[M - OH] ⁺	C ₃₇ H ₆₉ O ₄ ⁺
599.51	599.50 ⁷	DAG 36:4	[M - OH] ⁺	C ₃₉ H ₆₇ O ₄ ⁺
601.56	601.52 ⁷	DAG 36:3	[M - OH] ⁺	C ₃₉ H ₆₉ O ₄ ⁺
603.55	603.54 ⁷	DAG 36:2	[M - OH] ⁺	C ₃₉ H ₇₁ O ₄ ⁺

605.49	605.55 ⁷	DAG 36:1	[M - OH] ⁺	C ₃₉ H ₇₃ O ₄ ⁺
734.49	734.57 ⁷	PC 32:0	[M + H] ⁺	C ₄₀ H ₈₁ NPO ₈ ⁺
758.49	758.57 ⁷	PC 34:2	[M + H] ⁺	C ₄₂ H ₈₁ NPO ₈ ⁺
760.59	760.59 ⁷	PC 34:1	[M + H] ⁺	C ₄₂ H ₈₃ NPO ₈ ⁺
762.59	762.59 ⁷	PC 34:0	[M + H] ⁺	C ₄₂ H ₈₅ NPO ₈ ⁺
788.53	788.6 ⁹	PC 36:1	[M + H] ⁺	C ₄₄ H ₈₇ NPO ₈ ⁺
807.44	807.64 ⁹	SM d18:1/22:1	[M + Na] ⁺	C ₄₅ H ₉₀ N ₂ PO ₆ Na ⁺
809.44	809.64 ⁹	SM d18:1/22:0	[M + Na] ⁺	C ₄₅ H ₉₂ N ₂ PO ₆ Na ⁺

Table.S2 Comparison of lipids in positive mode between human and mice samples.

	NC	SCD	H-NC	H-CASE
PC Fragment	+	+	+	+
MAG 16:0	+	+	+	+
MAG 16:1	+	+	+	+
MAG 16:2	+	+	+	+
Cholesterol	+	+	+	+
Vita-E	+	+	+	+
LysoPC 16:0	-	+	-	+
LysoPC 16:1	-	+	-	+
LysoPC 16:2	-	+	-	+
DAG 30:0	+	+	-	+
DAG 30:1	+	+	-	+
DAG 30:2	+	+	-	+
DAG 32:0	+	-	+	-
DAG 32:1	+	+	+	-
DAG 32:2	+	-	+	-
DAG 34:0	+	-	+	-
DAG 34:1	+	-	+	-
DAG 34:2	+	-	+	-
DAG 36:1	+	-	+	-
DAG 36:2	+	-	+	-
DAG 36:3	+	-	+	-
DAG 36:4	+	-	+	-
PC 32:0	-	+	+	+
PC 34:2	-	+	+	+
PC 34:1	-	+	+	+
PC 34:0	-	+	+	+
PC 36:1	-	+	+	+
SM 40:1	-	+	-	-
SM 40:2	-	+	-	-

1. M. U. T. Le, J. G. Son, H. K. Shon, J. H. Park, S. B. Lee and T. G. Lee, *Biointerphases*, 2018, **13**, 03B414.
2. H. J. Yang, I. Ishizaki, N. Sanada, N. Zaima, Y. Sugiura, I. Yao, K. Ikegami and M. Setou, *Medical molecular morphology*, 2010, **43**, 158-164.
3. S. Tilvi, M. Majik and C. G. Naik, *European journal of mass spectrometry*, 2005, **11**, 345-351.
4. M. J. Picklo, B. K. Hanson and M. R. Bukowski, *Lipids*, 2019, **54**, 471-477.
5. M. Fillet, J. C. Van Heugen, A. C. Servais, J. De Graeve and J. Crommen, *Journal of chromatography. A*, 2002, **949**, 225-233.
6. W. Seefelder, G. Schwerdt, R. Freudinger, M. Gekle and H. U. Humpf, *Journal of chromatography. B, Analytical technologies in the biomedical and life sciences*, 2002, **780**, 137-144.
7. D. Debois, M. P. Bralet, F. Le Naour, A. Brunelle and O. Laprevote, *Analytical chemistry*, 2009, **81**, 2823-2831.
8. Y. Shi, J. Johnson, B. Wang, B. Chen, G. L. Fisher, G. Urabe, X. Shi, K. C. Kent, L. W. Guo and L. Li, *Journal of proteome research*, 2019, **18**, 1669-1678.
9. A. A. Vireque, A. Tata, O. F. Silva, E. G. LoTurco, A. Azzolini, C. R. Ferreira, M. H. Dantas, R. A. Ferriani and R. M. Reis, *Fertility and sterility*, 2016, **106**, 273-283 e276.